News
Novo Nordisk to cut 9,000 jobs
Digest more
In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
It's no secret that Novo Nordisk ( NVO -1.69%) and Eli Lilly ( LLY 1.57%) are toughing it out in the battle of the weight ...
GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.
Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more ...
Novo Nordisk, facing competition in the obesity drug market, has instructed employees to return to the office to enhance ...
Denmark's economy remains robust despite job cuts at Novo Nordisk , the finance minister told Reuters on Wednesday, ...
Discover why Novo Nordisk is a top buy with strong GLP-1 drug growth, robust fundamentals, and defensive value.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback